Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia
Nicolas G. Glynos, Jennifer Pierce, Alan K. Davis, Jenna McAfee, Kevin F. Boehnke
Journal of Psychoactive Drugs January 10, 2022 DOI: 10.1080/02791072.2021.2022817 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 354 |
| Population | North American adults with fibromyalgia |
| Topics | LSD Psilocybin |
| Keywords | Fibromyalgia Chronic pain Population Hallucinogen Perception Clinical psychology |
| Citations | 39 |
| Key findings | Among 354 adults with fibromyalgia, 29.9% had used a psychedelic, most reported neutral or positive experiences, and the majority expressed interest in psychedelic-based treatments for their pain. |
Abstract
Fibromyalgia (FM) is a difficult to treat chronic pain condition for which there is strong interest in alternative treatments. There is growing interest in the potential of psychedelic substances (e.g., psilocybin) in conjunction with psychotherapy to treat chronic pain. Via a cross-sectional, anonymous, online survey, we aimed to characterize knowledge, perceptions, and past use of serotonergic ("classic") and non-serotonergic psychedelics among a population of individuals with FM, and to investigate interest in psychedelic-based FM treatments. Among a North American population of 354 participants with FM, 29.9% reported past use of a psychedelic, with lysergic acid diethylamide (LSD) and psilocybin mushrooms being most commonly used. Perceptions of benefit from psychedelic use were generally neutral (59.4%) or positive (36.8%), with <3% reporting negative impacts on overall health or pain symptoms. Among 12 participants who used psychedelics with intentions of treating chronic pain, 11 reported improved symptoms. Regardless of past use, the majority of participants believed that psychedelics have potential for chronic pain treatments and would be willing to participate in a psychedelic-based clinical trial for their pain. These findings support the need for additional studies to understand the potential and effectiveness of psychedelic substances in managing FM symptoms.